Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $145,041.52 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 4,628 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $145,041.52. Following the transaction, the general counsel directly owned 28,836 shares of the company’s stock, valued at approximately $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, March 17th, Jonathan Allan sold 4,267 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total value of $140,853.67.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $33.51 on Friday. The stock’s 50 day moving average price is $32.61 and its 200 day moving average price is $30.09. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $40.22. The company has a market cap of $1.98 billion, a PE ratio of 50.01 and a beta of 1.07.

Analyst Upgrades and Downgrades

STOK has been the topic of a number of recent analyst reports. Guggenheim assumed coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 price target on the stock. Wedbush raised their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Wolfe Research began coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective on the stock. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a research report on Monday, December 15th. Finally, HC Wainwright increased their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Moderate Buy” and an average price target of $41.83.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. purchased a new position in Stoke Therapeutics during the 3rd quarter valued at about $1,062,000. Marshall Wace LLP raised its position in Stoke Therapeutics by 7.9% during the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after acquiring an additional 168,771 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Stoke Therapeutics in the third quarter valued at about $3,539,000. Franklin Resources Inc. lifted its holdings in shares of Stoke Therapeutics by 264.8% in the second quarter. Franklin Resources Inc. now owns 81,395 shares of the company’s stock valued at $924,000 after purchasing an additional 59,081 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after purchasing an additional 217,616 shares during the last quarter.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.